Form 8-K - Current report:
SEC Accession No. 0001829126-25-002001
Filing Date
2025-03-24
Accepted
2025-03-24 11:03:49
Documents
18
Period of Report
2025-03-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cyclacel_8k.htm   iXBRL 8-K 45389
2 EXHIBIT 3.1 cyclacel_ex3-1.htm EX-3.1 85736
3 EXHIBIT 10.1 cyclacel_ex10-1.htm EX-10.1 190402
4 EXHIBIT 99.1 cyclacel_ex99-1.htm EX-99.1 10879
5 GRAPHIC ex99-1_001.jpg GRAPHIC 6841
  Complete submission text file 0001829126-25-002001.txt   637983

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cycc-20250321.xsd EX-101.SCH 3744
7 XBRL DEFINITION FILE cycc-20250321_def.xml EX-101.DEF 26582
8 XBRL LABEL FILE cycc-20250321_lab.xml EX-101.LAB 36614
9 XBRL PRESENTATION FILE cycc-20250321_pre.xml EX-101.PRE 25206
20 EXTRACTED XBRL INSTANCE DOCUMENT cyclacel_8k_htm.xml XML 5887
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 25762912
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)